Public Market Listing
2186HKEX
Live quotes, historical charts, and market capitalization for Luye Pharma Group are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
9Total Assets
2Approved
3Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Phase 3 | Serotonin/norepinephrine/dopamine transporterSmall molecule | Major Depressive Disorder | |
LY01008No recent activity | Phase 3 | VEGF-AMonoclonal antibody | Non-Small Cell Lung Cancer |
LY03003No recent activity | Phase 3 | dopamineSmall molecule | Parkinson's Disease |
| Phase 2 | 5-HT2C/TAAR1 receptorSmall molecule | Alzheimer's DiseaseSchizophrenia | |
LY03009No recent activity | Phase 1 | dopamineSmall molecule | Parkinson's Disease |
| Phase 1 | Serotonin 5-HT2A receptor (antagonist / inverse agonist) · 5-HT2A/5-HT2C · 5-HT2A/2C receptorSmall molecule | Alzheimer's DiseaseParkinson's DiseaseSchizophrenia | |
| Phase 1 | Norepinephrine/dopamine transporter + GABA-A receptorSmall molecule | Major Depressive Disorder |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.